MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.35
-0.03 (-0.56%)
At close: Nov 28, 2025, 1:00 PM EST
5.31
-0.04 (-0.75%)
After-hours: Nov 28, 2025, 4:29 PM EST
MannKind Revenue
MannKind had revenue of $82.13M in the quarter ending September 30, 2025, with 17.20% growth. This brings the company's revenue in the last twelve months to $313.79M, up 17.44% year-over-year. In the year 2024, MannKind had annual revenue of $285.50M with 43.50% growth.
Revenue (ttm)
$313.79M
Revenue Growth
+17.44%
P/S Ratio
5.09
Revenue / Employee
$770,975
Employees
407
Market Cap
1.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MNKD News
- 17 days ago - MannKind to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 18 days ago - MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript - Seeking Alpha
- 19 days ago - MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease - GlobeNewsWire
- 23 days ago - MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes - GlobeNewsWire
- 23 days ago - MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025 - GlobeNewsWire
- 6 weeks ago - MannKind: Durable Cash Engine, Optional Catalysts Pending - Seeking Alpha